Michele C. Livesey, BS, MBA, brings to DIA more than two decades of drug development experience through managing and leading projects for Genentech, Inc., Barrier Therapeutics, Roche, and Afferent Pharmaceuticals. Michele has worked on monoclonal antibodies and small molecules in all stages of drug development through commercialization, including collaborations with international partners; her therapeutic experience includes oncology, dermatology, cardiovascular, virology, immunology, and pain. She currently owns and operates Livesey Consulting, which is focused on helping companies reach important milestones. She previously served as Vice President of Development Operations for Afferent Pharmaceuticals, where she was responsible for the staffing and oversight of non-clinical (toxicology and DMPK), CMC, regulatory, QA, project management, and general business operations.
Michelle has served DIA for more than a decade as an Annual Meeting speaker, session chair, and track chair, and has also provided leadership to the DIA Project Management SIAC, which she currently chairs. She has also chaired the conference jointly presented by the DIA PM SIAC and the Project Management Institute Special Interest Group (PMI SIG). Michelle earned her BS in Biological Sciences from California Polytechnic State University, San Luis Obispo, and her MBA with honors from Golden Gate University with an emphasis in Marketing & Operations and Supply Chain Management.